Area of research
Biomedical Engineering · Cancer Research
Research interest
Research focused on Olaparib and Photothermal therapy, with related work in Sonodynamic therapy, Sorafenib, KRAS. Notable publications include 'PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma', 'Efficacy and Safety of KRAS G12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study', and 'Coordination engineering of FeCo dual single-atom nanozymes with photothermal-enhanced cascaded catalysis for efficient pancreatic cancer immunotherapy'.
Experimental study on the vibrational relaxation mechanism of N <sub>2</sub> ( <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"> <mml:mrow> <mml:msup> <mml:mi>X</mml:mi> <mml:mn>1</mml:mn> </mml:msup> <mml:msubsup> <mml:mi>Σ</mml:mi> <mml:mi>g</mml:mi> <mml:mo>+</mml:mo> </mml:msubsup> </mml:mrow> </mml:math> , <i>v</i> = 6) molecules in collision with N <sub>2</sub> , O <sub>2</sub> , and CO
Efficacy and Safety of KRAS G12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study
Coordination engineering of FeCo dual single-atom nanozymes with photothermal-enhanced cascaded catalysis for efficient pancreatic cancer immunotherapy
Orchestrating apoptosis and ferroptosis through enhanced sonodynamic therapy using amorphous UIO-66-CoOx
PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma